Herpes ZosterVaccine to the Homebound Elderly: Prevention, Protection, and Access to Care [PDF]
, 2019 Herpes Zoster Vaccine to the Homebound Elderly: Prevention, Protection, and Access to Care Purpose: To increase the administration rate of the Herpes Zoster (Hz) vaccine Zostavax by 10% for persons 65 years and older in a home-based primary care practice,
Arts, Serena
core +1 more source
Comparison of the Immunogenicity of the LZ901 Vaccine and HZ/su Vaccine in a Mouse Model
VaccinesHerpes zoster (HZ) is an infectious disease caused by the reactivation of varicella zoster virus (VZV), with 68% of cases occurring in adults over 50 years of age.
Yaru Quan +9 more
doaj +1 more source
Epi Update for Friday, February 8, 2019 [PDF]
, 2019 Weekly Newsletter for the Center for Acute Disease Epidemiology of the Iowa Department of Public ...
core
Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23 [PDF]
Background Since 2021 a recombinant adjuvanted anti-Herpes Zoster vaccine(Recombinant Zoster Vaccine, RZV) is offered in Italy to high-risk patients. Few real-life data about RZV safety are available in target populations.
Di Lorenzo A +7 more
core +1 more source
npj VaccinesVaricella zoster virus (VZV) is a highly contagious human herpes virus responsible for causing chickenpox (varicella) and shingles (herpes zoster). Despite the approval of a highly effective vaccine, Shingrix®, the global incidence of herpes zoster is ...
Anannya Bhattacharya +13 more
doaj +1 more source
Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence
BMC Medicine, 2018 de Boer and colleagues present a cost-effectiveness analysis based in the Netherlands of two vaccines available for the prevention of herpes zoster. Zostavax® was the first vaccine available for the prevention of herpes zoster in older adults.
Chester B. Good +2 more
doaj +1 more source
Recombinant zoster vaccine and the risk of dementia. [PDF]
BACKGROUND: Herpes zoster is a potential risk factor for dementia. The effectiveness of the recombinant zoster vaccine for preventing dementia is uncertain.
Acharya, Nisha +3 more
core +1 more source
Vaccine: XHerpes zoster (HZ) induces significant pain and discomfort, which can seriously affect the quality of life of patients. At present, there is no specific treatment for HZ, and the mosteffective HZ control is vaccination. The main obstacle to developing an
Jiangang Zhang +10 more
doaj +1 more source
Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention
Expert Review of Vaccines, 2018 Introduction: GSK has developed a two-dose adjuvanted recombinant zoster vaccine (Shingrix, RZV) to protect people aged ≥50 years (50+) against herpes zoster (HZ) and its complications.
Nicolas Lecrenier +15 more
doaj +1 more source
Safety studies of aluminum in vaccines lack immunotoxicity analysis of this immunological adjuvant: Ignorance or deception? [PDF]
The safety studies most often referred by vaccine regulators when making claims about the safety of aluminum in vaccines, have ignored the immunotoxicity of aluminum. Vaccinologists admit that they neither understand the general immunological mechanisms
Arumugham, Vinu
core +1 more source